LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 236

Search options

  1. Book ; Conference proceedings: Proceedings of the Society of Hematologic Oncology 2015 annual meeting

    List, Alan F.

    (Clinical lymphoma, myeloma & leukemia ; volume 16, supplement 1 (August 2016))

    2016  

    Event/congress Society of Hematologic Oncology (3., 2015, HoustonTex., Annual Meeting)
    Author's details supplement editors: Alan F. List, MD; Hagop Kantarjian, MD and Emil J. Freireich, MD
    Series title Clinical lymphoma, myeloma & leukemia ; volume 16, supplement 1 (August 2016)
    Collection
    Language English
    Size S196 Seiten, Illustrationen
    Publisher Elsevier
    Publishing place New York, NY
    Publishing country United States
    Document type Book ; Conference proceedings
    Note Tagungsdaten: September 16-19, 2015, Hilton Americas in Houston, Texas
    HBZ-ID HT019106406
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 5903 -16,Suppl.1- not available for loan Zeitschriften-Lesesaal

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Book: Iron overload in myelodysplastic syndromes

    List, Alan F.

    diagnosis and management

    (Cancer control ; 17,1, Suppl.)

    2010  

    Author's details Alan F. List
    Series title Cancer control ; 17,1, Suppl.
    Collection
    Language English
    Size 11 S. : Ill., graph. Darst.
    Publisher Moffitt Cancer Center & Research Inst
    Publishing place Tampa, FL
    Publishing country United States
    Document type Book
    HBZ-ID HT016260841
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 4467 -17,1,Suppl.- not available for loan Zeitschriften-Lesesaal

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Book ; Conference proceedings: Recent advances in the treatment of MDS

    List, Alan F.

    a review of presentations from the 9th International Symposium on Myelodysplastic Syndromes, Florence, Italy, May 16 - 19, 2007

    (Clinical advances in hematology & oncology ; 5,7, Suppl. 10)

    2007  

    Event/congress International Symposium on Myelodysplastic Syndromes (9, 2007, Florenz)
    Author's details with an introduction by: Alan F. List
    Series title Clinical advances in hematology & oncology ; 5,7, Suppl. 10
    Collection
    Language English
    Size 14 S.
    Publisher Millennium Med. Publ
    Publishing place New York, NY
    Publishing country United States
    Document type Book ; Conference proceedings
    HBZ-ID HT016451038
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 6505 -5,Suppl.10- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Book: Evolving trends in the treatment of myelodysplastic syndrome (MDS)

    Bennett, John M. / List, Alan F.

    immunomodulation and beyond

    (Seminars in oncology ; 32,4, Suppl. 5)

    2005  

    Author's details Alan F. List, guest ed. Contributors John M. Bennett
    Series title Seminars in oncology ; 32,4, Suppl. 5
    Collection
    Language English
    Size S35 S. : Ill., graph. Darst.
    Publisher Saunders
    Publishing place Philadelphia, Pa
    Publishing country United States
    Document type Book
    HBZ-ID HT014489241
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 1348 -32,Suppl.5- not available for loan Zeitschriften-Lesesaal

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: New therapeutics for myelodysplastic syndromes.

    List, Alan F

    Leukemia research

    2012  Volume 36, Issue 12, Page(s) 1470–1474

    Abstract: While MDS was only recently viewed as an orphan disease without any FDA approved therapeutic options, the landscape has changed dramatically with a promise for development of exciting new therapeutics that parallels our growing understanding of the ... ...

    Abstract While MDS was only recently viewed as an orphan disease without any FDA approved therapeutic options, the landscape has changed dramatically with a promise for development of exciting new therapeutics that parallels our growing understanding of the pathobiology of the disease. An array of new agents is entering clinical development, many of which were not discussed in this review. Nevertheless, our paradigm for the approach to treatment of MDS can be expected to evolve with our ever expanding insight into the disease biology, targeting not only the MDS clone, but also the surrounding microenvironment while at the same time considering the context of the dynamics of disease pathogenesis.
    MeSH term(s) Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Azacitidine/pharmacology ; Azacitidine/therapeutic use ; Bone Marrow/drug effects ; Bone Marrow/pathology ; Chromosomes, Human, Pair 5 ; Glycine/analogs & derivatives ; Glycine/pharmacology ; Glycine/therapeutic use ; Humans ; Hydroxamic Acids/pharmacology ; Hydroxamic Acids/therapeutic use ; Myelodysplastic Syndromes/drug therapy ; Myelodysplastic Syndromes/genetics ; Myelodysplastic Syndromes/pathology ; Neoplastic Stem Cells/drug effects ; Neoplastic Stem Cells/pathology ; Sequence Deletion ; Sulfones/pharmacology ; Sulfones/therapeutic use ; Thalidomide/analogs & derivatives ; Thalidomide/pharmacology ; Thalidomide/therapeutic use ; Transforming Growth Factor beta/antagonists & inhibitors ; Tumor Microenvironment/drug effects ; p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors
    Chemical Substances Antineoplastic Agents ; Hydroxamic Acids ; Sulfones ; Transforming Growth Factor beta ; Thalidomide (4Z8R6ORS6L) ; ON 01910 (67DOW7F9GL) ; p38 Mitogen-Activated Protein Kinases (EC 2.7.11.24) ; lenalidomide (F0P408N6V4) ; tosedostat (KZK563J2UW) ; Azacitidine (M801H13NRU) ; Glycine (TE7660XO1C)
    Language English
    Publishing date 2012-12
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 752396-8
    ISSN 1873-5835 ; 0145-2126
    ISSN (online) 1873-5835
    ISSN 0145-2126
    DOI 10.1016/j.leukres.2012.08.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1321: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q.

    Talati, Chetasi / Sallman, David / List, Alan F

    Clinical lymphoma, myeloma & leukemia

    2018  Volume 18, Issue 10, Page(s) 629–635

    Abstract: Myelodysplastic syndrome (MDS) with deletion 5q [del(5q)] is a distinct clinical and pathologic disease subset that is exquisitely sensitive to lenalidomide for the treatment of red blood cell transfusion-dependent anemia. Lenalidomide resistance, ... ...

    Abstract Myelodysplastic syndrome (MDS) with deletion 5q [del(5q)] is a distinct clinical and pathologic disease subset that is exquisitely sensitive to lenalidomide for the treatment of red blood cell transfusion-dependent anemia. Lenalidomide resistance, including primary resistance, occurs by clonal evolution, which is frequently attributable to the presence of somatic mutations in the DNA-binding domain of the TP53 gene. The treatment options after development of resistance to lenalidomide are limited and consist of hypomethylating agents, clinical trials, and allogeneic hematopoietic stem cell transplantation. We discuss evidence-based strategies to devise a treatment algorithm for patients with MDS with del(5q).
    MeSH term(s) Algorithms ; Chromosome Deletion ; Chromosomes, Human, Pair 5/genetics ; Evidence-Based Practice ; Humans ; Myelodysplastic Syndromes/genetics ; Myelodysplastic Syndromes/therapy ; Prognosis
    Language English
    Publishing date 2018-07-30
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2540992-X
    ISSN 2152-2669 ; 2152-2650
    ISSN (online) 2152-2669
    ISSN 2152-2650
    DOI 10.1016/j.clml.2018.07.293
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5903: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Iron overload in myelodysplastic syndromes: diagnosis and management.

    List, Alan F

    Cancer control : journal of the Moffitt Cancer Center

    2010  Volume 17 Suppl, Page(s) 2–8

    Abstract: Myelodysplastic syndrome (MDS) is composed of a diverse spectrum of hematopoietic stem cell malignancies characterized by ineffective blood cell production. Many MDS patients are dependent on red blood cell (RBC) transfusions for symptomatic management ... ...

    Abstract Myelodysplastic syndrome (MDS) is composed of a diverse spectrum of hematopoietic stem cell malignancies characterized by ineffective blood cell production. Many MDS patients are dependent on red blood cell (RBC) transfusions for symptomatic management of refractory anemia. Iron overload ensues when the iron acquired from transfused RBCs exceeds body storage capacity, thereby raising the risk for end organ damage. This is of greatest concern in patients with lower-risk MDS whose expected survival is measured in years. Transfusion dependence is associated with shorter survival and an increased risk for progression to acute myeloid leukemia (AML) in transfusion-dependent patients. Application of recent advances in the treatment of MDS can reduce or eliminate the need for transfusions, thus minimizing the risk of iron overload. Case control studies, prospective surveys, and phase II studies indicate that iron chelation therapy reduces iron load as measured by changes in serum ferritin and may prolong overall survival. Iron chelation strategies include oral agents such as deferasirox (Exjade, Novartis Pharmaceuticals Corp, East Hanover, NJ), deferiprone (Ferriprox, Apotex Europe BV, Leiden, the Netherlands) and, for those patients who are intolerant of or for whom oral therapy is ineffective, parenteral administration of deferoxamine (Desferal, Novartis). This review presents the data related to iron overload in MDS, including its prevalence, diagnosis, clinical impact, and management.
    MeSH term(s) Erythrocyte Transfusion/adverse effects ; Humans ; Iron Chelating Agents/adverse effects ; Iron Chelating Agents/therapeutic use ; Iron Overload/diagnosis ; Iron Overload/drug therapy ; Iron Overload/epidemiology ; Iron Overload/etiology ; Myelodysplastic Syndromes/complications ; Myelodysplastic Syndromes/mortality ; Myelodysplastic Syndromes/therapy ; Practice Guidelines as Topic
    Chemical Substances Iron Chelating Agents
    Language English
    Publishing date 2010-01
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 1328503-8
    ISSN 1526-2359 ; 1073-2748
    ISSN (online) 1526-2359
    ISSN 1073-2748
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4467: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Proceedings of the Third Annual Meeting of the Society of Hematologic Oncology.

    List, Alan F / Kantarjian, Hagop / Freireich, Emil J

    Clinical lymphoma, myeloma & leukemia

    2016  Volume 16 Suppl, Page(s) S1

    Language English
    Publishing date 2016-08
    Publishing country United States
    Document type Editorial
    ZDB-ID 2540992-X
    ISSN 2152-2669 ; 2152-2650
    ISSN (online) 2152-2669
    ISSN 2152-2650
    DOI 10.1016/j.clml.2016.07.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5903: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Challenges in myelodysplastic syndromes: raising awareness and promoting new insight in therapeutic options.

    List, Alan F

    Cancer control : journal of the Moffitt Cancer Center

    2008  Volume 15 Suppl, Page(s) 2–3

    MeSH term(s) Humans ; Myelodysplastic Syndromes/therapy
    Language English
    Publishing date 2008-10
    Publishing country United States
    Document type Introductory Journal Article
    ZDB-ID 1328503-8
    ISSN 1526-2359 ; 1073-2748
    ISSN (online) 1526-2359
    ISSN 1073-2748
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4467: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin.

    Wang, Chen / McGraw, Kathy L / McLemore, Amy F / Komrokji, Rami / Basiorka, Ashley A / Al Ali, Najla / Lancet, Jeffrey E / Padron, Eric / Kosmider, Olivier / Fontenay, Michaela / Fenaux, Pierre / List, Alan F / Sallman, David A

    Haematologica

    2022  Volume 107, Issue 3, Page(s) 737–739

    MeSH term(s) Biomarkers ; Chromosome Deletion ; Chromosomes, Human, Pair 5/genetics ; Erythropoietin/therapeutic use ; Humans ; Lenalidomide/therapeutic use ; Myelodysplastic Syndromes/diagnosis ; Myelodysplastic Syndromes/drug therapy ; Myelodysplastic Syndromes/genetics
    Chemical Substances Biomarkers ; Erythropoietin (11096-26-7) ; Lenalidomide (F0P408N6V4)
    Language English
    Publishing date 2022-03-01
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 2333-4
    ISSN 1592-8721 ; 0017-6567 ; 0390-6078
    ISSN (online) 1592-8721
    ISSN 0017-6567 ; 0390-6078
    DOI 10.3324/haematol.2021.278855
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.76: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top